Form 4: aTyr Pharma CEO Sanjay Shukla Reports Stock Transactions
SEC Form 4 Filing
Sanjay Shukla, President and CEO of aTyr Pharma, reports the vesting of restricted stock units and subsequent acquisition of common stock.
Summary
- On February 3, 2025, Sanjay Shukla, the President and CEO of aTyr Pharma, vested 10,375 restricted stock units (RSUs) which converted into common stock on a one-for-one basis.
- Following the transaction, Shukla directly owns 146,923 shares of aTyr Pharma common stock.
- The RSUs were granted on February 3, 2022, and vest in four equal annual installments beginning on February 3, 2023, with full vesting by February 3, 2026.
- The RSUs are subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.
Sentiment
Score: 5
Explanation: This is a routine filing related to executive compensation and doesn't indicate any significant positive or negative sentiment.
Future Outlook
The remaining RSUs will continue to vest in equal annual installments until February 3, 2026.
Industry Context
This filing is a routine disclosure of insider transactions, providing transparency to investors regarding the holdings and transactions of company executives.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding executive compensation and ownership.
Key Dates
| Date | Description |
|---|---|
| 02/03/2022 | Date the restricted stock units (RSUs) were granted to Sanjay Shukla. |
| 02/03/2023 | First vesting date of the RSUs, with equal annual installments. |
| 02/03/2025 | Date of the reported transaction: vesting of 10,375 RSUs and acquisition of common stock. |
| 02/03/2026 | Final vesting date of the RSUs, when they will be fully vested. |
| 02/04/2025 | Date of the signature on the Form 4 filing. |
Keywords
aTyr Pharma, Sanjay Shukla, restricted stock units, RSUs, common stock, beneficial ownership, Form 4, SEC
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.